Ganem 2001.

Study characteristics
Methods	Study design: randomized controlled trial Study grouping: 2 groups, monoprophylaxis
Participants	Baseline characteristics Ondansetron Assessed for eligibility (n): ‐ Enrolled (n): ‐ Randomized (n): 27 Received treatment (n): NA Analysed (n): 27 Age (mean ± SD, median (IQR), median (range)): 35 ± 7 Weight (mean ± SD, median (IQR), median (range)): 62 ± 14 BMI (mean ± SD, median (IQR), median (range)): NA ASA I/II/III/IV (n): NA/NA/0/0 Gender (female in %): 100 Non‐smoker (%): NA History of PONV/motion sickness (%): 0/NA Type of general anaesthesia: TIVA (N₂O) Duration of anaesthesia or surgery (in min; as mean or median): 54 Use of perioperative opioids (if yes, which?): sufentanil for induction Type of surgery: diagnostic or surgical gynaecological laparoscopy Alizapride Assessed for eligibility (n): ‐ Enrolled (n): ‐ Randomized (n): 25 Received treatment (n): NA Analysed (n): 25 Age (mean ± SD, median (IQR), median (range)): 32 ± 6 Weight (mean ± SD, median (IQR), median (range)): 61 ± 10 BMI (mean ± SD, median (IQR), median (range)): NA ASA I/II/III/IV (n): NA/NA/0/0 Gender (female in %): 100 Non‐smoker (%): NA History of PONV/motion sickness (%): 0/NA Type of general anaesthesia: TIVA (N₂O) Duration of anaesthesia or surgery (in min; as mean or median): 53 Use of perioperative opioids (if yes, which?): sufentanil for induction Type of surgery: diagnostic or surgical gynaecological laparoscopy Included criteria: female, 21 to 50 years of age, ASA I or II, BMI < 30, submitted to diagnostic or surgical gynaecological laparoscopy Excluded criteria: current or previous gastric complaints, history of nausea and vomiting with previous anaesthesia, movement kinetosis, psychiatric disease, menstruating, alcohol and drug abusers Pretreatment: baseline characteristics (age, weight, ASA): no. Potential effect modifiers (gender, duration of anaesthesia, history of PONV): no; (history of motion sickness, non‐smoker, perioperative opioids): unclear
Interventions	Intervention characteristics Ondansetron Dose: 4 mg Time point of administration: immediately before anaesthetic induction Route of administration: IV Rescue antiemetics (if yes, which?): Intravenous ondansetron (4 mg) Alizapride Dose: 50 mg Time point of administration: immediately before anaesthetic induction Route of administration: IV Rescue antiemetics (if yes, which?): Intravenous ondansetron (4 mg)
Outcomes	Vomiting (0 to 1 hour, PACU) Outcome type: dichotomous outcome
Identification	Sponsorship source: NA Country: Brazil Setting: inpatient Author's name: Eliana Marisa Ganem Institution: Departamento de Anestesiologiada FMB ‐ UNESP Email: NA Address: Deptº de Anestesiologia da FMB ‐ UNESP, Distrito de Rubião Júnior, 18618‐970 ‐ Botucatu, SP Language: English Duration of study: NA Trial registry number: NA Study's primary outcome: NA
Notes	None
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "patients were randomly distributed in two groups according to the antiemetic drug, that is, group 1, ondansetron (4 mg) and group 2 alizapride (50 mg)" Judgement comment: no information on randomization method provided
Allocation concealment (selection bias)	Unclear risk	Judgement comment: no statement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Judgement comment: no statement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Judgement comment: no statement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Judgement comment: no missing outcome data
Selective reporting (reporting bias)	Unclear risk	Judgement comment: no reference to a study protocol or trial registry number reported
Other bias	Unclear risk	Quote: "groups were homogeneous as to age, weight, height and surgery and anesthesia duration (Table I)" Judgement comment: baseline characteristics (age, weight, ASA): no. Potential effect modifiers (gender, duration of anaesthesia, history of PONV): no; (history of motion sickness, non‐smoker, perioperative opioids): unclear